Stay updated on AVANOVA: Niraparib vs Niraparib-bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the AVANOVA: Niraparib vs Niraparib-bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the AVANOVA: Niraparib vs Niraparib-bevacizumab in Ovarian Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. This is a minor UI/metadata change with no impact on study details.SummaryDifference0.1%

- Check19 days agoChange DetectedFooter revision updated from v3.4.0 to v3.4.1. No changes to study content or eligibility criteria.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page now shows Revision: v3.4.1, replacing the previous Revision: v3.4.0. This is a minor template/version update that does not affect study details.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded a Show glossary control and updated page metadata to Revision: v3.4.0. Removed older labels such as Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check41 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4. No substantive changes to trial details are indicated.SummaryDifference0.1%

- Check62 days agoChange DetectedLocations sections were updated to include Massachusetts and Region Sjælland. The headings 'Massachusetts Locations' and 'Region Sjælland Locations' were removed and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to AVANOVA: Niraparib vs Niraparib-bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AVANOVA: Niraparib vs Niraparib-bevacizumab in Ovarian Cancer Clinical Trial page.